Malaysian Consensus Statement for the Diagnosis and Management of Acromegaly

Zanariah Hussein, Mohamed Long Bidin, Azmi Alias, Muthukkumaran Thiagarajan, Kartikasalwah Abdul Latif, Jeyakantha Ratnasingam, Wan Juani Wan Seman, Azraai Nasruddin

Abstract

In Malaysia, acromegaly is under-recognised with only 10-15% of the expected number of cases from prevalence estimates, having been diagnosed and managed in established endocrine centres with access to multidisciplinary care. This is mainly due to lack of awareness and standardised approach in diagnosing this disease resulting in delay in diagnosis and management with suboptimal treatment outcomes. This first Malaysian consensus statement on the diagnosis and management of acromegaly addresses these issues and is based on current best practices and latest available evidence so as to reduce the disease burden on acromegaly patients managed in the Malaysian healthcare system.

Keywords

acromegaly, consensus, Malaysia, growth hormone excess

Full Text:

Abstract HTML PDF

References

Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. PMID: 25356808. https://doi.org/10.1210/jc.2014-2700.

Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract. 2011;17(Suppl 4):1-44. PMID:21846616.

Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19(3):262-7. PMID: 26792654. PMCID: PMC4858553. https://doi.org/10.1007/s11102-015-0701-2.

Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Incidence and prevalence of acromegaly in the United States: A claims-based analysis. Endocr Pract. 2016;22(11):1327-35. PMID:27540880.

Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: A nationwide cohort study. Eur J Endocrinol. 2016;175(3):181-90. PMID: 27280374. https://doi.org/10.1530/EJE-16-0117.

Gatto F, Trifirò G, Lapi F, et al. Epidemiology of acromegaly in Italy: Analysis from a large longitudinal primary care database. Endocrine. 2018;61(3):533-41. PMID: 29797214. https://doi.org/10.1007/s12020-018-1630-4.

Kwon O, Song YD, Seong YK, Lee EJ, et al. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf). 2013;78(4):577-85. PMID: 22909047. https://doi.org/10.1111/cen.12020.

Sesmilo G, Webb SM; for the Neuroendocrinology Group of the Spanish Society of Endocrinology and Nutrition. Twelve years of the Spanish acromegaly registry: A historical view of acromegaly management in Spain. Endocrinol Nutr. 2010;57(2):39-42. PMID: 20189894.

https://doi.org/10.1016/j.endonu.2010.01.003.

Zarool-Hassan R, Conaglen HM, Conaglen JV, Elston MS. Symptoms and signs of acromegaly: An ongoing need to raise awareness among healthcare practitioners. J Prim Health Care. 2016;8(2):157-63. PMID: 27477558. https://doi.org/10.1071/HC15033 .

Hong JW, Ku CR, Kim SH, Lee EJ. Characteristics of acromegaly in Korea with a literature review. Endocrinol Metab (Seoul). 2013;28(3):164-8. PMID: 24396674. PMCID: PMC3811698. https://doi.org/10.3803/EnM.2013.28.3.164.

Sherlock M, Ayuk J, Tomlinson J, et al. c. MOrtality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-42. PMID: 20086217. https://doi.org/ 10.1210/er.2009-0033.

Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: A metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-7. PMID: 17971431. https://doi.org/10.1210/jc.2007-1191.

Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89-95. PMID: 18524797. https://doi.org/10.1530/EJE-08-0267.

Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab. 2008;93(6):2035-41. PMID: 18381584. https://doi.org/10.1210/jc.2007-2149.

Sesmilo G, Resmini E, Sambo M, et al. Prevalence of acromegaly in patients with symptoms of sleep apnea. PLoS ONE. 2017;12(9):e0183539. PMID: 28898247. PMCID: PMC5595301. https://doi.org/10.1371/journal.pone.0183539.

Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-202. PMID: 19884662. PMCID: PMC2769196. https://doi.org/10.1172/JCI39375.

Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398. PMID: 22518126. PMCID: PMC3296170. https://doi.org/10.1155/2012/540398.

Ribeiro-Oliveira A Jr., Barkan A. The changing face of acromegaly -- advances in diagnosis and treatment. Nat Rev Endocrinol. 2012;8(10):605-11. PMID: 22733271. https://doi.org/10.1038/nrendo.2012.101.

Giustina A, Chanson P, Bronstein M, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-8. PMID: 20410227. https://doi.org/10.1210/jc.2009-2670.

Arafat AM, Möhlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: The impact assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age and body mass index. J Clin Endocrinol Metab. 2008;93(4):1254-62. PMID: 18171702. https://doi.org/10.1210/jc.2007-2084.

Cazabat L, Souberbielle JC, Chanson P. Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary. 2008;11(2):129-39. PMID: 18418712. https://doi.org/10.1007/s11102-008-0113-7.

Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg. 2007;109(2):111-24. PMID: 17126479.

Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf). 1998;49(3):293-300. PMID: 9861318.

Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294-302. PMID: 22903574. PMCID: PMC3730092. https://doi.org/10.1007/s11102-012-0420-x.

Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243-8. PMID: 24566817. https://doi.org/10.1038/nrendo.2014.21.

Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-74. PMID: 14764779. https://doi.org/10.1210/jc.2003-031199.

Hannon MJ, Barkan AL, Drake WM. The role of radiotherapy in acromegaly. Neuroendocrinology. 2016;103(1):42-9. PMID: 26088716. https://doi.org/10.1159/000435776.

Marquez Y, Tuchman A, Zada G. Surgery and radiosurgery for acromegaly: A review of indications, operative techniques, outcomes and complications. Int J Endocrinol. 2012;2012:386401. PMID: 22518121. PMCID: PMC3303541. https://doi.org/10.1155/2012/386401.

Banerji D, Das NK, Sharma S, Jindal Y, Jain VK, Behari S. Surgical management of acromegaly: Long term functional outcome analysis and assessment of recurrent/residual disease. Asian J Neurosurg. 2016;11(3):261-7. PMID: 27366253. PMCID: PMC4849295. https://doi.org/10.4103/1793-5482.145354.

Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanriotide-induced GH and IGF-I decrease in acromegaly: a prospective multi-center study. J Endocrinol Invest. 2002;25(11):971-6. PMID: 12553557. https://doi.org/10.1007/BF03344070.

Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-68. PMID: 18477663. https://doi.org/10.1210/jc.2008-0027.

Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patient with acromegaly receiving lanreotide Autogel ® therapy: A randomised, placebo-controlled multicentre study with a 52 week open extension. Pituitary. 2010;13(1):18-28. PMID: 19639415. PMCID: PMC2807598. https://doi.org/10.1007/s11102-009-0191-1.

Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859-68. PMID: 17465997. PMCID: PMC1974838. https://doi.org/10.1111/j.1365-2265.2007.02825.x.

Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; UK Acromegaly Register Study Group (UKAR-3). Control of growth hormone and IGF1 in patients with acromegaly in the UK: Responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013;79(5):689-99. PMID: 23574573. https://doi.org/10.1111/cen.12207.

Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-61. PMID: 30050156. https://doi.org/10.1038/s41574-018-0058-5.

Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825-33. PMID: 24606084. PMCID: PMC4010703. https://doi.org/10.1210/jc.2013-3757.

Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE. 2012;7(5):e36411. PMID: 22574156. PMCID: PMC3344864. https://doi.org/10.1371/journal.pone.0036411.

Caron PJ, Bevan JS, Petersenn S, et al. Tumour shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-90. PMID: 24423301. PMCID: PMC4009579. https://doi.org/10.1210/jc.2013-3318.

Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343-9. PMID: 17892497. PMCID: PMC2268964. https://doi.org/10.1111/j.1365-2265.2007.03044.x.

Schopohl J, Strasburger CJ, Caird D, et al. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011;119(3):156-62. PMID: 21086246. https://doi.org/10.1055/s-0030-1267244.

Turner HE, Thornton-Jones VA, Wass JA. Systemic dose-extension of octreotide LAR: The importance of individual tailoring of treatment in patients with acromegaly. Clin Endcocrinol. 2004;61(2):224-31. PMID: 15272918. https://doi.org/10.1111/j.1365-2265.2004.02084.x.

Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: A randomised controlled trial. Eur J Endocrinol. 2009;161(2):331-8. PMID: 19465485. https://doi.org/10.1530/EJE-09-0372.

Giustina A, Mazziotti G, Cannavo S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: A randomised, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454-64. PMID: 28419317. https://doi.org/10.1210/jc.2017-00142.

Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791-9. PMID: 24423324. PMCID: PMC3965714. https://doi.org/10.1210/jc.2013-2480.

Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875-84. PMID: 25260838. https://doi.org/10.1016/S2213-8587(14)70169-X.

van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-9. PMID: 11734231.

Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374-8. PMID: 9467544. https://doi.org/10.1210/jcem.83.2.4556.

Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327-35. PMID: 21325455. https://doi.org/10.1210/jc.2010-2443.

Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systemic review and additional clinical data. Lancet Diabetes Endocrinol. 2014;3(11):906-13. PMID: 25466526. https://doi.org/10.1016/S2213-8587(14)70212-8.

Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209-15. PMID: 15272916. https://doi.org/10.1111/j.1365-2265.2004.02082.x.

Gatta B, Hau DH, Catargi B, Roger P, Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf). 2005;63(34):477-8. PMID: 16181243. https://doi.org/10.1111/j.1365-2265.2005.02329.x.

Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with acromegaly. Eur J Endocrinol. 2004;150(4):481-7. PMID: 15080777.

Minniti G, Scaringi C, Enrici RM. Radiation techniques for acromegaly. Radiat Oncol. 2011;6:167. https://doi.org/10.1186/1748-717X-6-167.

Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary. 2009;12(1):3-10. PMID: 18175223. https://doi.org/10.1007/s11102-007-0078-y.

Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus. 2010;29(4):E12. PMID: 20887122. https://doi.org/10.3171/2010.7.FOCUS10124.

Abu Dabrh AM, Asi N, Farah WH, et al. Radiotherapy versus radiosurgery in treating patients with acromegaly: A systemic reivew and meta-analysis. Endocr Pract. 2015;21(8):943-56. PMID: 26247235. https://doi.org/10.4158/EP14574.OR.

Silverstein JM. Need for improved monitoring in patients with acromegaly. Endocr Connect. 2015;4(4):R59-67. PMID: 26381160. PMCID: PMC4606206. https://doi.org/10.1530/EC-15-0064.

Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93(4):1324-30. PMID: 18230660. https://doi.org/10.1210/jc.2007-2104.

Freda PU. Monitoring of acromegaly: What should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf). 2009;71(2):166-70. PMID: 19226264. PMCID: PMC3654652. https://doi.org/10.1111/j.1365-2265.2009.03556.x.

Zirkzee EJ, Corssmit EP, Biermasz NR, et al. Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. J Clin Endocrinol Metab. 2004;89:4320-4. PMID: 15356027. https://doi.org/10.1210/jc.2003-032141.

Dina TS, Feaster SH, Laws E Jr, Davis DO. MR of the pituitary gland postsurgery: Serial MR studies following transsphenoidal resection. AJNR Am J Neuroradiol. 1993;14(3):763-9. PMID: 8517370.

Ciric I, Mikhael M, Stafford T, Lawson L, Garces R. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J Neurosurg. 1983;59(3):395-401. PMID: 6886753. https://doi.org/10.3171/jns.1983.59.3.0395.

Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocinol Metab. 2009;94(2):523-7. PMID: 19033371. https://doi.org/10.1210/jc.2008-1371.

Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer patients with acromegaly -- meta-analysis and systematic review. PLoS One. 2014;9(2):e88787. PMID: 24551163. PMCID: PMC3925168. https://doi.org/10.1371/journal.pone.0088787.